Author(s): You IC, Kang IS, Lee SH, Yoon KC
Abstract Share this page
Abstract PURPOSE: To investigate the efficacy of subconjunctival injection of bevacizumab in the treatment of patients with corneal neovascularization. METHODS: Twenty-nine eyes of 29 patients with corneal neovascularization were treated with subconjunctival injection [1.25 mg/0.05 ml (seven eyes), 2.5 mg/0.1 ml (15 eyes) and 5.0 mg/0.2 ml (seven eyes)] of bevacizumab. Best-corrected visual acuity, intraocular pressure and area of corneal neovascularization were measured before injection and at 1 week, 1 month and 3 months after treatment. RESULTS: At 1 week, the mean neovascularized corneal area decreased significantly to 85.5 +/- 18.0\% (p = 0.01) in the eyes treated with 2.5 mg bevacizumab and to 73.1 +/- 23.4\% (p = 0.02) in the eyes treated with 5.0 mg bevacizumab. At 3 months, the mean neovascularized corneal area was 93.6 +/- 10.6\% (p = 0.10 compared to baseline; p < 0.01 compared to 1 week) in the eyes treated with 2.5 mg bevacizumab and 83.3 +/- 25.8\% (p = 0.03 compared to baseline; p = 0.02 compared to 1 week) in the eyes treated with 5.0 mg bevacizumab. However, there were no significant changes in the areas of the eyes injected with 1.25 mg bevacizumab. CONCLUSION: Subconjunctival injection of bevacizumab can partially reduce corneal neovascularization in the short term, and the efficacy of this treatment correlates with the injection dose.
This article was published in Acta Ophthalmol
and referenced in Journal of Clinical & Experimental Ophthalmology